- Trial phase
- Phase 1/2
- Time to market
- Several years away at minimum. The drug is still in Phase 1/2 testing with no registrational trial initiated. Even if Phase 2 data support advancement, a Phase 3 program would take multiple years to complete before any regulatory filing.
- Why 2/10
- No hard dated catalyst (PDUFA, pivotal readout, or regulatory decision) is scheduled in the next ~12 months. The drug is in Phase 1/2 development, and BioNTech is a large-cap company (~$22B market cap) with a broad pipeline where this is one of several ADC assets, not the lead program.
Watch for further Phase 2 data readouts from the ongoing NCT05438329 trial, particularly in ovarian cancer (where Fast Track designation was granted) and NSCLC. Any announcement of a planned registrational Phase 3 trial would be the next meaningful catalyst. For now, the drug is too early-stage to be a standalone driver for BNTX shares.
Price Chart
Executive Summary
Sacituzumab drozuntecan (DB-1305/BNT325) is an investigational TROP2-targeted antibody-drug conjugate being co-developed by BioNTech (BNTX) and DualityBio. It is a next-generation ADC designed to compete in the same class as Gilead's approved Trodelvy (sacituzumab govitecan) and other TROP2 ADCs. The drug is still in early-stage Phase 1/2 clinical testing across multiple solid tumor types, with FDA Fast Track designation for platinum-resistant ovarian cancer. Preliminary Phase 2 data from the combination with pumitamig in first-line TNBC were presented at ESMO Breast Cancer 2026. For BioNTech investors, this is a small, early-stage piece of a much larger oncology pipeline pivot, with no near-term binary catalyst on the horizon.
How It Works
An antibody-drug conjugate (ADC) that works like a guided missile: one part is an antibody that seeks out and binds to a protein called TROP2 found on many cancer cells, and the other part is a chemotherapy drug (a topoisomerase I inhibitor) that gets released inside the cancer cell to kill it. TROP2 is overexpressed on several tumor types including breast, ovarian, and lung cancers.
Trial Status
The drug is being evaluated in an ongoing Phase 1/2a first-in-human study (NCT05438329) in patients with advanced or metastatic solid tumors. Phase 2 expansion cohorts are exploring the drug as monotherapy in pretreated triple-negative breast cancer (TNBC) and in combination with pumitamig (a PD-L1 x VEGF-A bispecific antibody) as first-line treatment for advanced/metastatic TNBC. Preliminary Phase 2 combination data were presented at ESMO Breast Cancer 2026 (May 2026) showing encouraging efficacy and manageable safety. The drug also has an FDA Fast Track designation for platinum-resistant ovarian cancer (granted January 2024).
The Two-Sided Case
Upcoming Catalysts
- Further Phase 2 data readouts from the ongoing NCT05438329 trial across TNBC, ovarian cancer, and NSCLC cohorts
- Potential initiation of a registrational/Phase 3 trial if Phase 2 data are supportive
- Additional combination data with pumitamig (BNT327) at future medical conferences
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BioNTech SE 6-K BNTX ·Originating report